• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

富山抗凝血酶III:遗传性异常抗凝血酶III中精氨酸-47被半胱氨酸取代,该抗凝血酶III缺乏肝素结合能力。

Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability.

作者信息

Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N

出版信息

Proc Natl Acad Sci U S A. 1984 Jan;81(2):289-93. doi: 10.1073/pnas.81.2.289.

DOI:10.1073/pnas.81.2.289
PMID:6582486
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC344661/
Abstract

Structural analyses of a hereditary abnormal antithrombin III, antithrombin III Toyama, which has normal progressive antithrombin activity but no heparin cofactor activity, have been carried out to elucidate the molecular abnormality causing recurrent thrombophlebitis of a patient and to identify an amino acid residue essential for the binding with heparin. Abnormal antithrombin III was reduced, S-pyridylethylated, and treated with cyanogen bromide. Eleven fragments were isolated by the combination of Sephadex G-50 gel filtration and reversed-phase HPLC and compared with those from normal antithrombin III. One large fragment (CN-III) that appeared to have a different amino acid composition from that of the corresponding fragment from normal antithrombin III was digested with trypsin, and the digests were separated by HPLC. The abnormal peptide was identified by comparing the peptide map with that from normal antithrombin III. Amino acid sequence analysis of the abnormal peptide indicated that the arginine-47 of normal antithrombin III had been replaced by cysteine in antithrombin III Toyama. One base mutation, C leads to T, in the 5' terminal position of the arginine-47 genetic codon (CGT) is probably responsible for this substitution. These results also suggest that arginine-47 is an essential amino acid residue for the binding with heparin.

摘要

对遗传性异常抗凝血酶III(富山抗凝血酶III)进行了结构分析,该抗凝血酶III具有正常的进行性抗凝血酶活性,但无肝素辅因子活性,目的是阐明导致一名患者反复发生血栓性静脉炎的分子异常,并确定与肝素结合所必需的氨基酸残基。将异常抗凝血酶III进行还原、S-吡啶基乙基化,并用溴化氰处理。通过Sephadex G-50凝胶过滤和反相高效液相色谱相结合的方法分离出11个片段,并与正常抗凝血酶III的片段进行比较。用胰蛋白酶消化一个似乎与正常抗凝血酶III相应片段氨基酸组成不同的大片段(CN-III),消化产物通过高效液相色谱分离。通过将肽图与正常抗凝血酶III的肽图进行比较来鉴定异常肽。异常肽的氨基酸序列分析表明,富山抗凝血酶III中正常抗凝血酶III的精氨酸-47被半胱氨酸取代。精氨酸-47遗传密码子(CGT)5'末端位置的一个碱基突变,即C突变为T,可能是这种取代的原因。这些结果还表明,精氨酸-47是与肝素结合所必需的氨基酸残基。

相似文献

1
Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability.富山抗凝血酶III:遗传性异常抗凝血酶III中精氨酸-47被半胱氨酸取代,该抗凝血酶III缺乏肝素结合能力。
Proc Natl Acad Sci U S A. 1984 Jan;81(2):289-93. doi: 10.1073/pnas.81.2.289.
2
Isolation and characterization of a hereditary abnormal antithrombin III 'Antithrombin III Toyama'.
Thromb Res. 1983 Jul 15;31(2):319-28. doi: 10.1016/0049-3848(83)90334-1.
3
Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to His.
Blood. 1987 May;69(5):1275-9.
4
Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity.
J Biol Chem. 1986 Jan 25;261(3):1174-6.
5
Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin.抗凝血酶III熊本II型;精氨酸393位点突变为组氨酸增加了抗凝血酶III对肝素的亲和力。
Am J Hematol. 1995 Jan;48(1):12-8. doi: 10.1002/ajh.2830480104.
6
Antithrombin III Toyama: a hereditary abnormal antithrombin III of a patient with recurrent thrombophlebitis.富山抗凝血酶III:一名复发性血栓性静脉炎患者的遗传性异常抗凝血酶III 。
Thromb Res. 1983 Jul 15;31(2):305-17. doi: 10.1016/0049-3848(83)90333-x.
7
[Abnormal antithrombin III: abnormalities of heparin or protease binding domain].
Rinsho Byori. 1993 May;41(5):492-505.
8
Single amino acid substitutions in the reactive site of antithrombin leading to thrombosis. Congenital substitution of arginine 393 to cysteine in antithrombin Northwick Park and to histidine in antithrombin Glasgow.
J Biol Chem. 1988 Apr 25;263(12):5589-93.
9
Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser.基于精氨酸47提出的抗凝血酶中的肝素结合位点。一种新的变体鲁昂-II,47位精氨酸突变为丝氨酸。
J Clin Invest. 1988 Apr;81(4):1292-6. doi: 10.1172/JCI113447.
10
Antithrombin Glasgow, 393 Arg to His: a P1 reactive site variant with increased heparin affinity but no thrombin inhibitory activity.
FEBS Lett. 1988 Apr 25;231(2):317-20. doi: 10.1016/0014-5793(88)80841-x.

引用本文的文献

1
Physiological significance of antithrombin D-helix interaction with vascular GAGs.抗凝血酶D螺旋与血管糖胺聚糖相互作用的生理意义。
Blood Adv. 2025 Mar 11;9(5):966-978. doi: 10.1182/bloodadvances.2024014756.
2
Diagnostic Utility of Whole Genome Sequencing After Negative Karyotyping/Chromosomal Microarray in Infants Born With Multiple Congenital Anomalies.对多发性先天畸形患儿行核型分析/染色体微阵列检测阴性后行全基因组测序的诊断效能。
J Korean Med Sci. 2024 Sep 23;39(36):e250. doi: 10.3346/jkms.2024.39.e250.
3
Analysis of AlphaFold and molecular dynamics structure predictions of mutations in serpins.丝氨酸蛋白酶抑制剂突变的 AlphaFold 和分子动力学结构预测分析。
PLoS One. 2024 Jul 5;19(7):e0304451. doi: 10.1371/journal.pone.0304451. eCollection 2024.
4
Molecular Mechanisms of the Impaired Heparin Pentasaccharide Interactions in 10 Antithrombin Heparin Binding Site Mutants Revealed by Enhanced Sampling Molecular Dynamics.增强采样分子动力学揭示 10 种抗凝血酶肝素结合位点突变体中肝素五糖相互作用受损的分子机制。
Biomolecules. 2024 Jun 4;14(6):657. doi: 10.3390/biom14060657.
5
Venous thromboembolic disease genetics: from variants to function.静脉血栓栓塞性疾病遗传学:从变异到功能。
J Thromb Haemost. 2024 Sep;22(9):2393-2403. doi: 10.1016/j.jtha.2024.06.004. Epub 2024 Jun 21.
6
Encephalomalacia/gliosis, deep venous thrombosis, and cancer in Arg393His antithrombin Hanoi and the potential impact of the β-amyloid precursor protein (APP) on thrombosis and cancer.在携带393位精氨酸突变为组氨酸的抗凝血酶的河内患者中出现的脑软化/胶质增生、深静脉血栓形成和癌症,以及β-淀粉样前体蛋白(APP)对血栓形成和癌症的潜在影响。
AIMS Neurosci. 2022 Apr 21;9(2):175-215. doi: 10.3934/Neuroscience.2022010. eCollection 2022.
7
Characterisation of a type II functionally-deficient variant of alpha-1-antitrypsin discovered in the general population.在普通人群中发现的一种 II 型功能缺陷型α-1-抗胰蛋白酶的特征。
PLoS One. 2019 Jan 11;14(1):e0206955. doi: 10.1371/journal.pone.0206955. eCollection 2019.
8
A novel variation of SERPINC1 caused deep venous thrombosis in a Chinese family: A case report.SERPINC1基因的一种新变异在中国一个家族中引发了深静脉血栓形成:病例报告。
Medicine (Baltimore). 2019 Jan;98(1):e13999. doi: 10.1097/MD.0000000000013999.
9
Expression and functional characterization of two natural heparin-binding site variants of antithrombin.抗凝血酶两种天然肝素结合位点变异体的表达和功能特征。
J Thromb Haemost. 2018 Feb;16(2):330-341. doi: 10.1111/jth.13920. Epub 2018 Jan 8.
10
Disease-causing mutations in the serpin antithrombin reveal a key domain critical for inhibiting protease activities.丝氨酸蛋白酶抑制剂抗凝血酶中的致病突变揭示了抑制蛋白酶活性的关键结构域。
J Biol Chem. 2017 Oct 6;292(40):16513-16520. doi: 10.1074/jbc.M117.787325. Epub 2017 Jul 25.

本文引用的文献

1
INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA.遗传性抗凝血酶缺乏导致血栓形成倾向。
Thromb Diath Haemorrh. 1965 Jun 15;13:516-30.
2
Tissue sulfhydryl groups.组织巯基
Arch Biochem Biophys. 1959 May;82(1):70-7. doi: 10.1016/0003-9861(59)90090-6.
3
Purification and partial characterization of a hereditary abnormal antithrombin III fraction of a patient with recurrent thrombophlebitis.复发性血栓性静脉炎患者遗传性异常抗凝血酶III组分的纯化及部分特性分析
Thromb Haemost. 1980 Oct 31;44(2):87-91.
4
Structural studies of the carbohydrate moiety of human antithrombin III.人抗凝血酶III碳水化合物部分的结构研究
Arch Biochem Biophys. 1980 Aug;203(1):458-65. doi: 10.1016/0003-9861(80)90199-x.
5
Familial functional antithrombin III deficiency.家族性功能性抗凝血酶III缺乏症。
Scand J Haematol. 1980 Feb;24(2):105-9. doi: 10.1111/j.1600-0609.1980.tb02352.x.
6
The covalent nature of the human antithrombin III--thrombin bond.人抗凝血酶III与凝血酶键的共价性质。
Biochem J. 1980 Sep 1;189(3):481-9. doi: 10.1042/bj1890481.
7
The N-terminal sequence of human plasma histidine-rich glycoprotein homologous to antithrombin with high affinity for heparin.
FEBS Lett. 1982 May 17;141(2):222-4. doi: 10.1016/0014-5793(82)80052-5.
8
The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin.抗凝血酶的活性位点。从与因子IXa、因子Xa和凝血酶形成的复合物中释放出相同的经蛋白水解切割的抑制剂形式。
J Biol Chem. 1982 Mar 10;257(5):2406-11.
9
Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma.肝素辅因子II。人血浆中一种依赖肝素的凝血酶抑制剂的纯化及特性
J Biol Chem. 1982 Mar 10;257(5):2162-9.
10
Isolation and characterization of a hereditary abnormal antithrombin III 'Antithrombin III Toyama'.
Thromb Res. 1983 Jul 15;31(2):319-28. doi: 10.1016/0049-3848(83)90334-1.